Histopathological and receptor characteristics of 59 hepatocellular carcinomas, two liver adenomas, and two liver samples
| Code | Age/sex | Histopathology | SS-R1-160 | VIP/PACAP-R†† | SP-R |
|---|---|---|---|---|---|
| 46 | 39/M | HCC; trabecular; G1 | − | + (2787)1-150 | − |
| 11 | 62/M | HCC; trabecular; solid; G1 | − | + (2039)1-150 | − (v +) |
| 17 | 45/F | HCC; trabecular; solid; G1 | + (364) | + (7575)1-150 | − |
| 49 | 31/M | HCC; fibrolamellar; G1 | − | + (734)1-153 | − (v +) |
| 52 | 26/F | HCC; fibrolamellar; G1 | + (142) | + (928)1-150 | + (v +) |
| 74 | 21/F | HCC; fibrolamellar; G1 | − | − | − (v +) |
| 42 | 67/M | HCC; pseudoglandular; G1/G2 | − | − | − |
| 15 | 77/F | HCC; trabecular; G1/G2 | + (348) | − | − (v +) |
| 62 | 72/M | HCC; trabecular; G1/G2 | − | + (728)1-150 | − (v +) |
| 66 | 58/M | HCC; trabecular; G1/G3 | + (341) ht | − | − (v +) |
| 3 | 69/M | HCC; pseudogland; G2 | − | + (1144)1-150 | − (v +) |
| 28 | 66/M | HCC; pseudoglandular, trabecular; G2 | + (281) | + (901) ht1-150 | − (v +) |
| 30 | 35/M | HCC; pseudoglandular, trabecular; G2 | + (3490) | − | − (v +) |
| 47 | 74/F | HCC; pseudoglandular, trabecular; G2 | − | − | − (v +) |
| 63 | 70/F | HCC; pseudoglandular, trabecular; G2 | − | +/− (3972)1-150 1-154 | − (v +) |
| 64 | 69/M | HCC; pseudoglandular, trabecular; G2 | − | + (1613)1-150 | − (v +) |
| 21 | 68/M | HCC; trabecular; G2 | − | + (1934)1-150 | − (v +) |
| 22 | 68/F | HCC; trabecular; G2 | − | − | − |
| 24 | 57/F | HCC; trabecular; G2 | + (196) | + (3518)1-151 | − (v +) |
| 27 | 64/M | HCC; trabecular; G2 | − | − | − (v +) |
| 31 | 70/M | HCC; trabecular; G2 | − | + (667)1-153 | − (v +) |
| 45 | 43/M | HCC; trabecular; G2 | + (630) | + (735)1-150 | − (v +) |
| 57 | 55/M | HCC; trabecular; G2 | − | − | − |
| 69 | 74/M | HCC; trabecular; G2 | − | − | − |
| 75 | 60/M | HCC; trabecular; G2 | − | + (785) ht1-150 | − |
| 8 | 48/F | HCC; trabecular, solid; G2 | − | − | − |
| 14 | 71/F | HCC; trabecular, solid; G2 | + (314) | + (5085) ht/liver + (10312)1-150 | + (v +) |
| 12 | 75/M | HCC; solid; G2 | − | + (1186)1-150 | − (v +) |
| 20 | 36/F | HCC; solid; G2 | − | + (329)1-153 | − (v +) |
| 72 | 66/F | HCC; solid; G2 | + (176) | + (471)1-153 | − (v +) |
| 18 | 35/M | HCC; fibrolamellar; G2 | − | +1-152 | − (v +) |
| 6 | 68/M | HCC; trabecular; G2/G3 | + (1702) ht (G3 −, G2 +/−) | + (4872) hm1-150 | − (v +) |
| 58 | 63/M | HCC; trabecular, sclerosing; G2/G3 | − | − | − (v +) |
| 53 | 62/M | HCC; solid; G2/G3 | − | + (646)1-153 | − (v +) |
| 70 | 48/M | HCC; solid; G2/G3 | + (394) | − | − (v +) |
| 10 | 72/M | HCC; pseudoglandular, trabecular; G3 | + (258) | + (1537)/liver + (8313)1-150 | − (v +) |
| 19 | 76/M | HCC; pseudoglandular, trabecular; G3 | − | − | − |
| 23 | 67/F | HCC; trabecular; G3 | + (949) | − | − |
| 39 | 75/M | HCC; trabecular; G3 | − | − | − (v +) |
| 43 | 68/M | HCC; trabecular; G3 | + (364) | − | − (v +) |
| 67 | 59/M | HCC; trabecular; G3 | + (2825) | − | − (v +) |
| 71 | 72/F | HCC; trabecular; G3 | − | + (1250)1-150 | − |
| 2 | 47/M | HCC; trabecular, solid; G3 | − | − | − (v +) |
| 7 | 56/M | HCC; trabecular, solid; G3 | − | − | − |
| 25 | 50/F | HCC; trabecular, solid; G3 | + (144) | − | + (v +) |
| 13 | 56/M | HCC; solid; G3 | + (310) | + (685)/liver + (12691)1-150 | − (v +) |
| 29 | 67/M | HCC; solid; G3 | − | + (291)1-150 | − (v +) |
| 34 | 75/F | HCC; solid; G3 | + (2787) ht | + (293)/liver + (7466)1-150 | − (v +) |
| 37 | 56/M | HCC; solid; G3 | + (1442) | − | − (v +) |
| 44 | 67/F | HCC: solid; G3 | − | − | − (v +) |
| 48 | 72/M | HCC; solid; G3 | + (369) | − | − (v +) |
| 59 | 56/F | HCC; solid; G3 | − | − | − (v +) |
| 60 | 66/M | HCC; solid; G3 | + (3622) | − | − (v +) |
| 65 | 61/M | HCC; solid; G3 | − | − | − |
| 68 | 79/M | HCC; solid; G3 | − | + (1093)1-150 | − (v +) |
| 73 | 79/M | HCC; solid; G3 | + (130) | + (319)1-150 | − (v +) |
| 26 | 65/M | HCC; solid; G4 | − | − | − |
| 35 | 55/F | HCC; solid; G4 | + (184) ht | − | − |
| 1 | 41/F | HCC; anaplastic; G4 | − | − | − (v +) |
| 33 | 33/M | Liver adenoma | − | − | − (v +) |
| 51 | 54/M | Liver adenoma | − | + (6899)1-150 | − (v +) |
| 32 | 46/F | Liver | − | + (8183)1-150 | − (v +) |
| 38 | 72/M | Liver | − | + (5312)1-150 | − (v +) |
↵1-150 Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase activating peptide (PACAP) II receptors identified as VIP1/PACAP II subtype (with high affinity for VIP1 selective analogue).
↵1-151 VIP1/PACAP II receptors and PACAP I receptors.
↵1-152 No VIP/PACAP II receptors but PACAP I receptors.
↵1-153 VIP/PACAP II receptors without VIP1/VIP2 subtyping.
↵1-154 : + pseudoglandular part; − trabecular part.
↵1-160 In parentheses: density of125I-Tyr3-octreotide binding sites (dpm/mg tissue).
††In parentheses: density of 125I-VIP binding sites (dpm/mg tissue).
ht, heterogeneous receptor distribution; hm, homogeneous receptor distribution; v +, receptor positive vessels; HCC, hepatocellular carcinoma.